OBJECTIVE

This study evaluates the impact of rosuvastatin on the effectiveness of litholytic and eradication therapy in gallstone disease (GSD) patients.

MATERIALS AND METHODS

In a study involving 122 GSD patients with gallstones smaller than 10 mm, participants were divided into three groups. Group 1 (42 patients) had GSD and hypercholesterolemia (HC) and received ursodeoxycholic acid (UDCA) at 15 mg/kg. Group 2 (40 patients) with GSD and HC received a combination of UDCA at 15 mg/kg and rosuvastatin at 20 mg. Group 3 (40 individuals) had GSD but no HC and received UDCA at 15 mg/kg. The 12-month treatment included an upper endoscopy with a gastric antral mucosa biopsy for Helicobacter pylori (H. pylori) confirmation. H. pylori-positive patients received 14-day triple eradication therapy, with results assessed after four weeks. Abdominal ultrasounds were performed at baseline, 3, 6, 9, and 12 months, and lipid profiles were measured before treatment and at 6 and 12 months.

RESULTS

Groups with HC had higher H. pylori infection rates: 66.6% (Group 1) and 67.5% (Group 2). Group 2 achieved the highest H. pylori eradication rate at 96.2%, while Group 1 had the lowest at 78.5% (p<0.05). After 12 months, Group 2 showed the most effective litholysis, with positive lipid profile changes.

CONCLUSION

For GSD patients with HC and/or H. pylori infection, rosuvastatin can be considered an adjunct in litholytic and eradication therapy. This approach showed promise for H. pylori eradication and favorable lipid profile improvements, offering a potential therapeutic strategy for this patient group.